A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapvir for HIV Pre-Exposure Prophylaxis (PrEP) in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary people 18 Years of Age or Older who Have Sex with Male Partners and are at Risk of HIV Infection.

Need additional information?

Please indicate if you heard about us by any of these means: